Published online before print June 16, 2005, doi: 10.1161/01.ATV.0000174589.70190.e2
© 2005 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
An Oral ApoJ Peptide Renders HDL Antiinflammatory in Mice and Monkeys and Dramatically Reduces Atherosclerosis in Apolipoprotein E–Null Mice
From the David Geffen School of Medicine at UCLA (M.N., S.T.R., B.J.V.L., A.C.W., S.H., G.H., E.B., A.M.F.), Los Angeles, Calif; and the Department of Medicine (G.M.A., D.W.G., V.K.M., M.N.P.), Atherosclerosis Research Unit, University of Alabama at Birmingham.
Correspondence to Mohamad Navab, PhD, Room 47-123 CHS, Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, California 90095-1679. E-mail mnavab{at}mednet.ucla.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— To determine the properties of a peptide synthesized from D-amino acids corresponding to residues 113 to 122 in apolipoprotein (apo) J.
Methods and Results— In contrast to D-4F, D- [113–122]apoJ showed minimal self-association and helicity in the absence of lipids. D-4F increased the concentration of apoA-I with pre-ß mobility in apoE-null mice whereas D- [113–122]apoJ did not. After an oral dose D- [113–122]apoJ more slowly associated with lipoproteins and was cleared from plasma much more slowly than D-4F. D- [113–122]apoJ significantly improved the ability of plasma to promote cholesterol efflux and improved high-density lipoprotein (HDL) inflammatory properties for up to 48 hours after a single oral dose in apoE-null mice, whereas scrambled D- [113–122]apoJ did not. Oral administration of 125 µg/mouse/d of D- [113–122]apoJ reduced atherosclerosis in apoE-null mice (70.2% reduction in aortic root sinus lesion area, P=4.3x10–13; 70.5% reduction by en face analysis, P=1.5x10–6). In monkeys, oral D- [113–122]apoJ rapidly reduced lipoprotein lipid hydroperoxides (LOOH) and improved HDL inflammatory properties. Adding 250 ng/mL of D-[113–122]apoJ (but not scrambled D- [113–122]apoJ) to plasma in vitro reduced LOOH and increased paraoxonase activity.
Conclusions— Oral D- [113–122]apoJ significantly improves HDL inflammatory properties in mice and monkeys and inhibits lesion formation in apoE-null mice.
Oral D- [113–122]apoJ, a peptide synthesized from D-amino acids corresponding to residues 113 to 122 in apolipoprotein J, significantly improves HDL inflammatory properties in mice and monkeys and inhibits lesion formation in apoE-null mice.
Key Words: atherosclerosis • apolipoprotein J • high-density lipoproteins • lipoproteins • inflammation
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Recently there has been great interest in the use of apolipoprotein (apo)A-I and apoA-I mimetic peptides as potential therapeutic agents for atherosclerosis.1–7 The literature contains reports of only 2 small (18 residue) peptides with efficacy in mouse models of atherosclerosis, 4F and 5F. Both are examples of class A amphipathic helical peptides, and only 4F synthesized from D-amino acids (D-4F) has been reported to be active after oral administration.4–9 The ability of these peptides to inhibit atherosclerosis in mouse models has been closely correlated with the ability of these peptides to inhibit LDL-induced monocyte chemotactic activity (MCA) in a human artery wall coculture.9 While the apoA-I mimetic peptides have many properties in common with apoA-I, there are some important differences. Human apoA-I binds inflammatory lipids in such a way that the apoA-I–lipid complex can still activate cells to produce MCA (ie, if low-density lipoprotein [LDL] and human apoA-I are added together in a coincubation with human artery wall cells, the LDL is still able to stimulate the cells to produce MCA).10 However, if apoA-I is added to the artery wall cells and removed before addition of LDL or if apoA-I is incubated with LDL and then separated from the LDL before the addition of the LDL to the cells (a preincubation), the LDL cannot induce the cells to produce MCA.10 In contrast, after D-4F binds these inflammatory lipids, the peptide–lipid complex will not stimulate the cells to produce MCA (ie, adding D-4F and LDL together in a coincubation prevents the LDL from causing the cells to produce MCA).9,11
ApoJ also bound these inflammatory lipids so that they were inactive in a coincubation (ie, LDL added to human artery wall cells in the presence of apoJ could not induce MCA).12 We hypothesized that short amphipathic helical sequences in apoJ could mimic the action of apoJ. Using the LOCATE program13 we identified 17 potential G* amphipathic helixes in the mature apoJ protein (Table). We synthesized seven of these sequences and tested them in our artery wall cell culture model and all but 1 [[146–156]apoJ]) was effective in decreasing LDL-induced MCA (Table). However, only 2 were as effective as the intact apoJ protein in decreasing LDL-induced MCA (sequences [113–122]apoJ and [336–357]apoJ); the other five were less active than the intact apoJ protein. These 2 sequences ([113–122]apoJ and [336–357]apoJ) were synthesized from all D-amino acids and tested in preliminary studies for their ability to inhibit atherosclerosis in apoE-null mice after oral administration. Only the sequence [113–122]apoJ inhibited lesion formation in vivo in these preliminary studies. Subsequent studies constitute the basis of this report and show that oral D-[113–122]apoJ renders high-density lipoprotein (HDL) antiinflammatory in both mice and monkeys and dramatically reduces atherosclerosis in apoE-null mice.
|
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
The peptide Ac-L-V-G-R-Q-L-E-E-F-L-NH2 corresponding to amino acids 113 to 122 in apoJ (D-[113–122]apoJ), scrambled D-[113–122]apoJ (Ac-L-R-G-V-Q-L-L-E-F-E-NH2), D-4F, and scrambled D-4F were synthesized with all D-amino acids using solid phase synthesis as previously described.4,6,914C-D-[113–122]apoJ was synthesized using solid-phase synthesis in which Gly of Fmoc-Gly and the acetylating agent acetic acid were 14C-labeled. D-4F was iodinated using the iodogen procedure (Pierce Chemical Co). All other materials were from previously cited sources.6
Animals
Female apoE-null mice on a C57BL/6J background were purchased from Jackson Laboratories and maintained on a chow diet (Ralston Purina). Cynomolgus monkeys, 2 males and 2 females weighing approximately 4 kg were obtained from the UCLA Division of Laboratory and Animal Medicine and fed high-fiber Purina monkey chow, 8 biscuits twice daily. The UCLA Animal Research Committee approved all animal studies.
Lipoproteins, Cell Cultures, Monocyte Chemotaxis, and Lesion Scoring
Lipoproteins, cell cultures, and monocytes were prepared and monocyte chemotaxis assays were performed as described.6,14 Plasma samples were fractionated by a gel permeation fast protein liquid (FPLC) system as previously described.6 Aortic lesions were scored as previously described.4,15 ApoA-I in pre-ß migrating particles was determined in 2-D gels using Western blots, a Typhoon scanner, and Image Quant software as previously described6,16 and expressed as the percent of total apoA-I in pre-ß migrating particles.
Other Procedures
Lipoprotein cholesterol concentrations, paraoxonase activity, and lipoprotein lipid hydroperoxides were determined as previously described.6 Circular dichroism studies were preformed as previously described.9,17,18 Cellular cholesterol efflux studies were performed as previously described.19 Statistical significance was determined using Model I ANOVA and significance defined as P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Differences in the Physical-Chemical Properties of D-4F and D-[113–122]ApoJ
There was a significant concentration-dependent CD change with D-4F but not with D-[113–122]apoJ in PBS indicating a tendency for self-association for D-4F but not for D-[113–122]apoJ (data not shown). D-4F showed significant helicity in PBS (42%), which was only modestly improved in the presence of lysophosphatidylcholine (LysoPC), sodium dodecyl sulfate (SDS), and trifluoroethanol (TFE) (eg, in 1% SDS the percent helicity was 56%). In contrast, D-[113–122]apoJ had relatively poor helicity in PBS (13%), but there was nearly a 3-fold increase in helicity in the presence of LysoPC, SDS, and TFE (eg, in 1% SDS the percent helicity was 31%).
D-[113–122]ApoJ in Human Artery Wall Cell Cultures
D-[113–122]apoJ potently inhibited LDL-induced MCA in vitro in a coincubation (data not shown) and thus acts like apoJ12 and D-4F9 and is different from apoA-I.10
Oral D-[113–122]ApoJ in ApoE-Null Mice
Based on the counts in the plasma after an oral dose of 14C-D-[113–122]apoJ or 125I-D-4F both peptides showed low absorption in apoE-null mice (Figure 1A and 1B).
|
As shown in Figure 1A after an oral dose, D-[113–122]apoJ slowly associated with lipoproteins and was cleared from plasma much more slowly than D-4F (Figure 1B) indicating significant differences in the kinetics of association and clearance between D-[113–122]apoJ and D-4F. Additionally it should be noted that [113–122]apoJ (in contrast to D-4F) largely remained in the fractions to the right of mature HDL in the FPLC chromatogram even after 36 hours (compare Figure 1A to Figure 1B). Similar results were obtained when 14C-D-[113–122]apoJ was added to mouse chow instead of administering it in water (data not shown).
We previously reported that D-4F causes increased formation of pre-ß HDL.6 Figure 1C again demonstrates that oral D-4F significantly increases the amount of apoA-I in pre-ß migrating particles in apoE-null mice and also demonstrates that scrambled D-4F and D-[113–122]apoJ did not.
The ability of apoE-null mouse plasma to promote cholesterol efflux from macrophages via the ABCA1 pathway was poor compared with normal human HDL, but after oral administration of either D-[113–122]apoJ or D-4F apoE-null mouse plasma was as effective as normal human HDL (Figure 1D).
Administering D-[113–122]apoJ to apoE-null mice converted their HDL to antiinflammatory within 4 hours and the HDL remained significantly antiinflammatory for up to 48 hours after a single oral dose, whereas the same dose of scrambled D-[113–122]apoJ had no effect (Figure 1E).
Figure 1F and 1G demonstrate that administering D-[113–122]apoJ to apoE-null mice for 24 weeks dramatically reduced atherosclerosis.
The mice described in Figure 1F and 1G that received D-[113–122]apoJ had slightly but significantly lower plasma total cholesterol levels (584±45 versus 499±49 mg/dL; P=0.021), higher HDL-cholesterol levels (26.4±4.0 versus 32.4±1.1 mg/dL; P=0.012), and triglyceride levels that were not significantly different (153±11 versus 136±19 mg/dL) for mice on chow versus chow plus peptide, respectively. HDL from the mice described in Figure 1F and 1G was isolated by FPLC, and paraoxonase activity was determined and normalized to HDL-cholesterol and was found to be approximately doubled in the mice that received D-[113–122]apoJ (P=0.0013).
The D-[113–122]apoJ peptide only constituted 0.00625% of the chow diet by weight, and there was no significant difference in chow consumption, body weight, liver weight, or heart weight between the mice that received chow or chow plus peptide (data not shown).
Oral D-[113–122]apoJ in Monkeys
We previously reported that oral D-4F reduced lipoprotein lipid hydroperoxides and improved HDL-inflammatory properties in monkeys.20 D-[113–122]apoJ also reduced lipoprotein lipid hydroperoxides in monkeys (Figure 2A and 2B) and also rendered monkey HDL antiinflammatory 3 hours after oral administration (data not shown). Consistent with the plasma kinetics seen in mice (Figure 1A, 1B, and 1E), lipoprotein inflammatory properties remained significantly improved for up to 24 hours after a single oral dose of D-[113–122]apoJ in monkeys (Figure 2C and 2D). After another wash out period of more than 1 week from the experiments described in Figure 2C and 2D the monkeys were bled (time zero) and then given by gastric gavage 20 mg of D-[113–122]apoJ and bled 6 hours later and paraoxonase activity and plasma lipids were determined. Paraoxonase activity significantly increased in the monkeys (P<0.001) (data not shown). The plasma total cholesterol levels, HDL-cholesterol levels, and non-HDL–cholesterol levels at time zero in these monkeys were 114±2 mg/dL, 59±1, and 55 mg/dL, respectively. The values 6 hours after dosing were not significantly different being 114±2 mg/dL, 58±1 mg/dL, and 56 mg/dL, respectively. There was a slight but significant decrease in plasma triglycerides 6 hours after the monkeys received oral D-[113–122]apoJ (25±14 versus 19±12 mg/dL, P=0.04).
|
4 Kg) and 2 male (
Addition of ng/mL of D-[113–122]apoJ to Plasma In Vitro Decreases Lipid Hydroperoxides and Increases Paraoxonase Activity
We previously reported that addition of D-4F to human plasma in vitro at a concentration of 250 ng/mL reduced lipid hydroperoxides and increased paraoxonase activity.21 As shown in Figure 3A, apoE-null mouse plasma has very little HDL-cholesterol compared with the cholesterol in the fractions containing apoB and the distribution of lipoproteins was not changed with the addition of D-[113–122]apoJ versus scrambled D-[113–122]apoJ. Addition of 250 ng/mL of D-[113–122]apoJ (but not scrambled D-[113–122]apoJ] to apoE-null mouse plasma in vitro significantly reduced the lipid hydroperoxide content of LDL (Figure 3B) and HDL (Figure 3C) and increased paraoxonase activity (Figure 3D).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In vitro, D-[113–122]apoJ acts like D-4F9 and apoJ12 and not like apoA-I10 in that D-[113–122]apoJ is active in a coincubation (ie, in the presence of D-[113–122]apoJ LDL cannot induce human artery wall cells to produce MCA). Based on our previous work this would suggest that D-[113–122]apoJ is able to effectively bind and sequester the lipid hydroperoxides necessary for oxidation of the LDL phospholipids, which when oxidized cause the artery wall cells to produce monocyte chemoattractant protein-1 (MCP-1).6,10,22
In vivo, oral D-4F causes the movement of apoA-I into particles with pre-ß mobility in apoE-null mice whereas D-[113–122]apoJ does not (Figure 1C). The ability of D-4F to form pre-ß HDL may be attributable to the ability of D-4F to promote the separation of cholesterol from phospholipid.18 It is possible that this property of D-4F may accelerate the normal process whereby apoA-I dissociates from alpha migrating HDL and forms pre-ß HDL. It is also possible that the differences in physical-chemical properties of D-[113–122]apoJ are such that this is not the case with this peptide, and thus it does not cause the formation of pre-ß HDL. Alternatively, the rapid association of D-4F with mature HDL (Figure 1B) compared with the minimal association of[113–122]apoJ with mature HDL (Figure 1A) may allow D-4F (but not [113–122]apoJ) to accelerate the normal process whereby apoA-I dissociates from alpha migrating HDL and forms pre-ß HDL. Future experimentation will be needed to determine the cause for the differences between D-4F and [113–122]apoJ in inducing the formation of pre-ß HDL. Despite the failure of oral D-[113–122]apoJ to cause the formation of pre-ß HDL in apoE-null mice, this peptide significantly improved the ability of apoE-null mouse plasma to promote cholesterol efflux from macrophages (Figure 1D).
The association of D-[113–122]apoJ with lipoproteins was much slower after an oral dose than was the case for D-4F, and the rate of clearance from the plasma was much faster after an oral dose of D-4F than was the case after administration of D-[113–122]apoJ (Figure 1A and 1B). The prolonged residence-time of D-[113–122]apoJ in components of plasma smaller than lipoproteins as determined by FPLC analysis (Figure 1A) suggests that the initial binding of this peptide is to a non-lipoprotein and that it is released from this plasma compartment only slowly.
As shown in Figure 3A apoE-null mouse plasma has very little HDL-cholesterol compared with the cholesterol in the fractions with apoB containing lipoproteins. The association of D-[113–122]apoJ (Figure 1A) with FPLC fractions containing HDL suggests a very high affinity for HDL compared with the apoB containing lipoproteins.
The inflammatory properties of HDL from apoE-null mice given D-[113–122]apoJ were significantly improved for up to 48 hours after a single oral dose (Figure 1E). In contrast, scrambled D-[113–122]apoJ did not alter the inflammatory properties of HDL from these mice indicating that the effect of D-[113–122]apoJ is highly specific.
Oral D-[113–122]apoJ dramatically reduced atherosclerosis in apoE-null mice (Figure 1F and 1G) and was associated with a significant increase in HDL-cholesterol levels (26.4±4.0 versus 32.4±1.1 mg/dL) and an increase in HDL paraoxonase activity. The magnitude of the reduction in atherosclerosis in the apoE-null mice approaches that reported4 for D-4F. However, D-4F has also been shown to dramatically synergize with statins and cause lesion regression in old apoE-null mice.23 Future studies will be required to determine whether this is also the case for D-[113–122]apoJ.
We have observed in 2 different monkey colonies (Figure 2 for a colony at UCLA and data not shown for a colony in Michigan) that Cynomolgus monkeys have proinflammatory HDL (ie, their HDL fails to inhibit LDL-induced MCA). This proinflammatory HDL in animals with very little LDL is probably a positive evolutionary selection factor because it would presumably enhance protection from infection via the innate immune system while not contributing to a negative selection factor (atherosclerosis) in the absence of elevated levels of apoB containing lipoproteins.
Similar to D-4F,20 D-[113–122]apoJ rapidly reduced lipoprotein lipid hydroperoxide levels in Cynomolgus monkeys (Figure 2A and 2B) and improved lipoprotein inflammatory properties for up to 24 hours after a single oral dose (Figure 2C and 2D). The rapid onset of action in both apoE-null mice (Figure 1E) and monkeys (Figure 2A and 2B), coupled with the prolonged effects after a single oral dose in both species (Figures 1E, 2C, and 2 
D) compare favorably with reports4,6,20 on D-4F (and data not shown). The sustained effect of D-[113–122]apoJ after a single oral dose would be consistent with the prolonged residence-time in plasma (Figure 1A).
A common mechanism for the beneficial effects of both D-4F and D-[113–122]apoJ may relate to the ability of both peptides to bind and sequester oxidized lipids and activate antioxidant enzymes such as paraoxonase21 (Figure 3B through 3D). Bielicki and Forte reported that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity (LCAT)24 and Forte and colleagues25 demonstrated altered activities of LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice that correlated with plasma levels of oxidized lipids. One common mechanism for D-4F and D-[113–122]apoJ might be the binding and sequestration of oxidized lipids that inhibit a series of antioxidant enzymes. With these oxidized lipids effectively sequestered (and presumably removed from the circulation), the activity of these antioxidant enzymes might be released from inhibition leading to further destruction of the oxidized lipids and the start of a positive feedback loop that amplifies the destruction of these proinflammatory lipids and results in an antiinflammatory environment.
|
Acknowledgments |
|---|
This work was supported in part by US Public Health Service grants HL-30568 and HL-34343 and the Laubisch, Castera, and M.K. Gray Funds at UCLA.
|
Footnotes |
|---|
M.N., S.H., S.T.R., G.M.A., and A.M.F. are principals in Bruin Pharma.
Received February 24, 2005; accepted June 3, 2005.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes. A randomized controlled trial. JAMA. 2003; 290: 2292–2300.
2. Rader DJ. High-density lipoproteins as an emerging therapeutic target for atherosclerosis. JAMA. 2003; 290: 2322–2324.
3. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Datta G, Garber D, Fogelman AM. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Current Opinion in Lipidology. 2004; 15: 645–659.[CrossRef][Medline] [Order article via Infotrieve]
4. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM. Oral administration of an apoA-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002; 105: 290–292.
5. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L, Nayak DP, Hama S, Navab M, Fogelman AM. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation. 2002; 106: 1127–1132.
6. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM. Oral D-4F causes formation of pre-ß high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apoE-null mice. Circulation. 2004; 109: r120–r125.
7. Van Lenten BJ, Wagner AC, Navab M, Anantharamaiah GM, Hui EK-W, Nayak DP, Fogelman AM. D-4F, an apoA-I mimetic peptide inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation. 2004; 110: 3252–3258.
8. Garber DW, Datta G, Chaddha M, Palgunachari MN, Hama SY, Navab M, Fogelman AM, Segrest JP, Anantharamaiah GM. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res. 2001; 42: 545–552.
9. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Mishra VK, Epand RM, Epand RF, Lund-Katz S, Phillips MC, Segrest JP, Anantharamaiah GM. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res. 2001; 42: 1096–1104.
10. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, Reddy ST, Sevanian A, Fonarow GC, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000; 41: 1495–1508.
11. Datta G, Epand RF, Epand RM, Chaddha M, Kirksey MA, Garber DW, Lund-Katz S, Phillips MC, Hama S, Navab M, Fogelman AM, Palgunachari MN, Segrest JP, Anantharamaiah GM. Aromatic residue position on the nonpolar face of class A amphipathic helical peptides determines biological activity. J Biol Chem. 2004; 279: 26509–26517.
12. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, Castellani LW, Brennan M-L, Lusis AJ, Fogelman AM. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997; 99: 2005–2019.[Medline] [Order article via Infotrieve]
13. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM. The amphipathic helix in the exchangeable apolipoproteins: a review of secondary structure and function. J Lipid Res. 1992; 33: 141–166.[Abstract]
14. Seager-Danciger J, Lutz M, Hama S, Cruz D, Castrillo A, Lazaro J, Phillips R, Premack B, Berliner J. Method for large scale isolation, culture and cryopreservation of human monocytes suitable for chemotaxis, cellular adhesion assays, macrophage and dendritic cell differentiation. J Immunol Methods. 2004; 288: 123–134.[CrossRef][Medline] [Order article via Infotrieve]
15. Navab M, Hama S, Hough G, Fogelman AM. Oral synthetic phospholipids (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. Circulation. 2003; 108: 1735–1739.
16. Jiang X-C, Francone OL, Bruce C, Milne R, Mar J, Walsh A, Breslow JL, Tall AR. Increased pre-ß-high density lipoprotein apolipoprotein AI and phospholipids in mice expressing the human phospholipids transfer protein and human apolipoprotein AI transgenes. J Clin Invest. 1996; 96: 2373–2380.
17. Calero M, Tokuda T, Rostagno A, Kumar A, Zlokovic B, Frangione B, Ghiso J Functional and structural properties of lipid-associated apolipoprotein J (clusterin). Biochem J. 199l; 344: 375–383.[CrossRef]
18. Epand RM, Epand RF, Sayer BG, Melacini G, Palgunachari MN, Segrest JP, Anantharamaiah GM. An apolipoprotein AI mimetic peptide: Membrane interactions and the role of cholesterol. Biochemistry. 2004; 43: 5073–5083.[CrossRef][Medline] [Order article via Infotrieve]
19. Zheng L, Nukuna B, Brennan M-L, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, Ischiropoulos H, Smith JD, Kinter M, Hazen SL. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004; 114: 529–541.[CrossRef][Medline] [Order article via Infotrieve]
20. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004; 45: 993–1007.
21. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol. 2005; 25: 1325–1331.
22. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, Subbanagounder G, Faull KF, Reddy ST, Miller NE, Fogelman AM. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. 2000; 41: 1481–1494.
23. Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS, Garber DW, Handattu S, Fogelman AM. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E null mice. Arterioscler Thromb Vasc Biol. 2005; 25: 1426–1432.
24. Bielicki JK, Forte TM. Evidence that lipid hydroperoxides inhibit plasma lecithin:cholesterol acyltransferase activity. J Lipid Res. 1999; 40: 948–954.
25. Forte TM, Subbanagounder G, Berliner JA, Blanche PJ, Clermont AO, Jia Z, Oda MN, Krauss RM, Bielicki JK. Altered activities of anti-atherogenic enzymes, LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J Lipid Res. 2002; 43: 477–485.
This article has been cited by other articles:
 |
|
 |
|
  M. Navab, I. Shechter, G.M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, and A. M. Fogelman Structure and Function of HDL Mimetics Arterioscler Thromb Vasc Biol, February 1, 2010; 30(2): 164 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Hoofnagle and J. W. Heinecke Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins J. Lipid Res., October 1, 2009; 50(10): 1967 - 1975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Kim, E.-K. Yoo, J.-Y. Kim, Y.-K. Choi, H.-J. Lee, J.-K. Kim, N. H. Jeoung, K.-U. Lee, I.-S. Park, B.-H. Min, et al. Protective Role of Clusterin/Apolipoprotein J Against Neointimal Hyperplasia via Antiproliferative Effect on Vascular Smooth Muscle Cells and Cytoprotective Effect on Endothelial Cells Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1558 - 1564. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Navab, P. Ruchala, A. J. Waring, R. I. Lehrer, S. Hama, G. Hough, M. N. Palgunachari, G. M. Anantharamaiah, and A. M. Fogelman A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids J. Lipid Res., August 1, 2009; 50(8): 1538 - 1547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. deGoma, R. L. deGoma, and D. J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2199 - 2211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M S Lee and R. P Choudhury Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets Heart, May 1, 2007; 93(5): 559 - 564. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Handattu, D. W. Garber, D. C. Horn, D. W. Hughes, B. Berno, A. D. Bain, V. K. Mishra, M. N. Palgunachari, G. Datta, G. M. Anantharamaiah, et al. ApoA-I Mimetic Peptides with Differing Ability to Inhibit Atherosclerosis Also Exhibit Differences in Their Interactions with Membrane Bilayers J. Biol. Chem., January 19, 2007; 282(3): 1980 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kontush and M. J. Chapman Functionally Defective High-Density Lipoprotein: A New Therapeutic Target at the Crossroads of Dyslipidemia, Inflammation, and Atherosclerosis Pharmacol. Rev., September 1, 2006; 58(3): 342 - 374. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||